

# Genetics and the placebo effect: the placebome

Kathryn T. Hall<sup>1,2</sup>, Joseph Loscalzo<sup>3</sup>, and Ted J. Kaptchuk<sup>1,2</sup>

<sup>1</sup> Program in Placebo Studies, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA

<sup>2</sup> Department of Medicine, Division of General Medicine and Primary Care, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA

<sup>3</sup> Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA

**Placebos are indispensable controls in randomized clinical trials (RCTs), and placebo responses significantly contribute to routine clinical outcomes. Recent neurophysiological studies reveal neurotransmitter pathways that mediate placebo effects. Evidence that genetic variations in these pathways can modify placebo effects raises the possibility of using genetic screening to identify placebo responders and thereby increase RCT efficacy and improve therapeutic care. Furthermore, the possibility of interaction between placebo and drug molecular pathways warrants consideration in RCT design. The study of genomic effects on placebo response, 'the placebome', is in its infancy. Here, we review evidence from placebo studies and RCTs to identify putative genes in the placebome, examine evidence for placebo–drug interactions, and discuss implications for RCTs and clinical care.**

## Biomarkers of the placebo response: an overview

From the early use of bread pills as patient appeasement [1] to clinical trial nuisance variables, placebos and placebo effects (see [Glossary](#)) have a troubled history [2,3]. Recent innovative neuroimaging [4] and physiological experiments [5] have fostered the current viewpoint that placebo effects are biological responses to psychosocial environmental cues surrounding the administration of inactive (or active) treatments. Such placebo research has established that the placebo response is more than patient report bias, regression to the mean, or spontaneous remission [6–8]. As a result of these developments, placebo responses are emerging as a legitimate series of biological reactions that must be rigorously characterized to facilitate efficient pharmaceutical development and optimal clinical care.

Predicting who will be a placebo responder could be of value to both researchers and patients. In drug development, detecting a difference between active intervention and the placebo control is an underlying goal of RCTs. Being able to identify and exclude individuals who are more likely to respond to placebos could enhance trial designs seeking to find such a difference. Potential cost

savings due to reduction of sample size could be of benefit for drug development [9]. From a clinical perspective, knowing likely responders could modify treatment approaches (including patient–provider interactions) and allow for more careful titrations of medication dosages. Therefore, precise knowledge of the contribution of genomic variation to placebo effects promises to guide the development of more efficient controls in experiments and refinements of clinical practice.

In the past, scientists used behavioral instruments such as personality measures to predict placebo responders [10,11]. This approach has had limited success because these blunt instruments proved no match for the complex interplay of shifting states that may modify an individual's placebo response. Not only do clinical trial researchers have to contend with the type, duration, and severity of the condition, but the practitioner's 'bedside manner' and the patient's beliefs, hopes, expectations, and previous experiences [12] also make predicting the placebo response an ongoing challenge.

There is growing evidence that the individual's genetic makeup (a stable trait) influences clinical outcomes and potentially may allow for identification of placebo responders. Individual variations in the genome can give rise to differences in the functioning of myriad interacting gene, miRNA, and protein molecular networks. The recent availability of large-scale genomic, RNA, and protein measurements ('-omics') offers a potential new approach by which to understand, control, and harness the placebo response. However, despite the promise of this technology to guide the development of safer and more effective pharmaceuticals and personalized medicine, no comprehensive studies (e.g., genome-wide association studies; GWAS) to identify genomic correlates (or other biomarkers) of the placebo response, 'the placebome', have, to our knowledge, been performed.

The search for genomic biomarkers of the placebo response is in its infancy and, thus, we initiate the discussion of placebo genomics with the search for placebo response genes. Indeed, there have been many placebo-controlled RCTs with GWAS data, but they all lack a key dimension: a no-treatment control (NTC). A NTC is one of the few methodologies that can disentangle genuine psychosocial and physiological placebo responses to the symbols, rituals, and behaviors of the clinical encounter ('placebo

Corresponding author: Hall, K.T. ([ktHall@bidmic.harvard.edu](mailto:ktHall@bidmic.harvard.edu)).

Keywords: placebo; RCT; COMT; no treatment control; pharmacogenomics.

1471-4914/

© 2015 Elsevier Ltd. All rights reserved. <http://dx.doi.org/10.1016/j.molmed.2015.02.009>

## Glossary

**-omics:** an informal term referring to biological studies of molecules derived from or affecting the genome. These studies tend to be large in scale and the terms used to describe them end in ‘-omics’ (i.e., genomics, transcriptomics, proteomics, and metabolomics).

**Dopamine:** a catecholamine neurotransmitter or hormone that is important in signaling in the reward-motivation and motor control neural pathways. Dysfunction in the dopamine system is associated with several diseases and disorders, including schizophrenia, attention deficit hyperactivity disorder, addiction, and Parkinson’s disease.

**Drug efficacy:** the ability of a drug to produce a clinically beneficial effect. In a RCT, drug efficacy is determined by subtracting the primary clinical outcome in the placebo arm from the outcome in the drug treatment arm.

**Endocannabinoids:** a group of neuromodulatory lipids that have a role in modulating mood, appetite, memory, and pain sensation.

**Endogenous opioids:** naturally occurring peptides that relieve pain and signal reward in the brain.

**Genome-wide association study (GWAS):** a study used to scan and compare variation in genes across large numbers of individuals to identify genetic associations with disease incidence, treatment, and prevention.

**Interactome:** the term given to the entire set of molecular interactions within the cell. Therefore, the interactome seeks to define the physical and biochemical influences that gene, protein, small molecule drugs, miRNA, and other biomolecular networks exert on each other across normal or disease states.

**Minor-allele frequency (MAF):** used to describe how many people in a given population carry the least common allele. If in a given population, the MAF is 20%, then among population members, one in five chromosomes will carry the minor allele and four out of five chromosomes will carry the other genetic variant, or major allele.

**No treatment control (NTC):** an arm of a RCT in which randomly allocated subjects receive no treatments or interventions. This arm is sometimes called the wait list and the subjects are observed during the time of the trial. When studying placebo effects, the NTC can be an important control for the placebo arm of a RCT because it allows for an estimate of the genuine effects of a placebo intervention by controlling for spontaneous remission, regression to the mean, and normal waxing and waning of an illness in the placebo treatment arm.

**Nocebo effects:** considered the opposite of placebo effects. They are negative or adverse effects in response to an inert or placebo treatment.

**Nociceptive pain:** caused by stimulation of pain receptors in response to pressure, temperature, or irritating substances that send pain signals to the brain in response to injury or the possibility of injury. Antinociceptive treatments are designed to reduce such pain.

**Pharmacogenomics:** the study of how variation in the genome modifies individual response to drug treatment. The goal of pharmacogenomics is to use -omics data to guide the development of safer and more effective and, therefore, more personalized medicines.

**Placebo:** an inert treatment (e.g., dummy pills, fake injections, or sham surgery) designed to simulate a biomedical intervention within a RCT. Placebo response is the positive health benefits that patients receive in response to the symbols, rituals, and behaviors embedded in a clinical encounter.

**Placebome:** the hypothesized group of genome-related or derived molecules (i.e., genes, proteins, or miRNAs) that affect an individual’s response to placebo treatment.

**Randomized controlled clinical trial (RCT):** the gold standard for clinical studies in which participants are randomized to an active exposure or inert treatment arm of the trial. In placebo-controlled RCTs, participants are blinded to their treatment allocation and the results are used to test the efficacy or effectiveness of a drug or active intervention.

**Serotonin:** a monoamine neurotransmitter that is important in regulating mood, appetite, and cognitive functions, including memory and learning. SSRIs are antidepressants that are designed to increase serotonin levels.

**Single nucleotide polymorphisms (SNPs):** sites in the genome that differ in the DNA nucleotide sequence and, thus, give rise to genetic variability.

effects’) from spontaneous remission, regression to the mean, and the natural waxing and waning of illness. The main reason for this gap is simple: trials are interested in testing drug efficacy, and randomization to active treatment or placebo is thought to be a sufficient measure by which to allow clinical trial researchers to discern specific drug responses. Any improvement in subjects in the placebo arm has generally been ignored and viewed as an intrusive but necessary hurdle to overcome. However,

without studies that have NTCs as a control for the placebo arm, an accurate and comprehensive view of the set of potential placebo genetic biomarkers (the placebome) may not easily become available.

Despite this limitation, we can cull information about the genes involved in the placebome from three types of available studies in the literature: (i) a small RCT investigating placebo responses that included a NTC and conducted a candidate gene analysis; (ii) placebo-controlled RCTs in patients that included an analysis of candidate genes that coincide with genes implicated in the placebo response mechanism; and (iii) experimental studies in healthy subjects that examined candidate placebo genes. Although the generalizability of placebo response mechanisms from healthy volunteers to patients is not yet understood, the results of these studies can yield some insight into potential genes constituting the placebome.

However, the importance of identifying genes involved in the placebo response is not limited to outcomes in the placebo arm of RCTs. An important underlying assumption in RCTs is that, in aggregate, the main difference between the drug treatment and placebo arms is solely the effect of the active drug. However, a not uncommon and striking observation in RCTs that include genotyping of putative placebo pathway genes, is effect modification of the outcomes by placebo genotype in both the placebo arm and the drug treatment arm; in other words, there is evidence of gene–placebo–drug interactions. The possibility that, in some drug treatment paradigms, there is placebo–drug interaction as a result of genetic variation in placebo pathway genes suggests that we need to refine and recalibrate the assumptions of placebo controls in RCTs in some cases.

## Towards a physiology of the placebo response

The first solid evidence that there is an underlying biological process that gives rise to the placebo response (that the placebo effect is more than ‘report-bias’ patients pleasing the experimenter, or overenthusiastic researchers) was first published in 1978 followed by a series of studies on placebo effects in molar extraction [13]. In this and subsequent studies, Levine *et al.* demonstrated that the pain suppression system of the body could be induced by placebo and was, in turn, blocked by naloxone, an opioid receptor antagonist. Further studies by this group hypothesized that morphine and placebo might share a common opioidergic mechanism and estimated the placebo analgesic effect to be equivalent to up to 8 mg of morphine [14,15]. As the opioid system emerged as a major underlying biochemical mechanism involved in placebo analgesia, the role of mu opioid receptors in placebo analgesia was further confirmed in neuroimaging studies [16–19]. These studies used pain models to demonstrate that expectation of analgesia induced activity in key areas in the brain involved in endogenous opioid transmission and analgesia. Since these early studies, placebo researchers also raised the possibility that the opioidergic system is not exclusively responsible for placebo analgesia [12]. Further work dissected the role of endogenous opioids in placebo analgesia, showing that naloxone only partially blocked placebo analgesia in subjects conditioned with the nonsteroidal

anti-inflammatory drug ketorolac [20], while the cholecystokinin antagonist proglumide potentiated placebo pain relief [21–23]. More recently, the endocannabinoid system has also been implicated in placebo analgesia in physiological experiments [24].

Although the analgesic effects of opioid receptor signaling explained how placebo treatment might mitigate pain in many situations, it did not address how placebos mediated clinical benefit in other treatment paradigms. Subsequently, researchers postulated that expectancy of benefit or reward might be a key general mediating process in the placebo response [25]. To test whether neural correlates of reward were also associated with anticipation of placebo responses, Scott *et al.* used a pain model that looked at both opioid and dopamine receptor activation in brain regions associated with reward [26]. They showed that both pathways were activated in anticipation of the placebo response and that higher levels of dopamine receptor activation were seen in individuals with higher placebo responses. Conversely, they found that in individuals who reported an increase in pain (i.e., placebo nonresponders or, more accurately, negative placebo or nocebo responders), dopaminergic and opioid signaling was reduced. Positron emission tomography (PET) studies on the placebo response in Parkinson's disease also showed that striatal dopaminergic neurons were activated in anticipation of benefit or reward when a placebo was administered [27,28]. Neuroimaging studies of subjects with major depression suggest that placebo treatment causes changes in brain function [29,30]. Given the especially high rate of placebo responses in depression RCTs [31,32], the serotonin pathway has also been discussed in relation to placebo responses.

This growing list of neurotransmitters and neurological pathways mediating the placebo response provides a framework for candidate gene analyses. Indeed, treatment outcomes in the placebo arms of trials that have assessed genetic variation in the dopaminergic, opioid, cannabinoid, and serotonergic pathways suggest that genetic variation in the synthesis, signaling, and metabolism of these neurotransmitters contributes to variation in the placebo response (Table 1).

### Genetic variation in the dopamine pathway

The emergence of the dopamine-mediated reward centers as being central to the underlying physiology of the

placebo response makes genetic variation in dopamine metabolism and signaling pathway genes prime candidates for placebo response biomarkers. Rs4680, the most studied polymorphism in dopamine metabolism, is in the gene encoding catechol-O-methyltransferase (*COMT*), an enzyme that metabolizes dopamine and other catecholamines [33]. The rs4680 SNP has been implicated in modifying clinical outcomes in both the placebo and drug treatment arms of numerous diverse trials [34–44]. Rs4680 encodes a valine (val)-to-methionine (met) change at codon 158 (val158met), resulting in a three–four times reduction in enzymatic activity. Homozygotes of the less-active met allele have been associated with higher levels of dopamine in the prefrontal cortex, a region implicated in the placebo response pathway [45,46]. Rs4680 is a common polymorphism, and the prevalence of the less-frequent met allele or minor allele (MAF) is reported as 0.37 in Caucasians [47], but varies by race and/or ethnicity [48,49]. The high MAF of rs4680 translates to an estimated 20–25% of met/met individuals in Caucasian populations. Finding common SNPs is an important criterion when considering the feasibility of using genotype as a predictive placebo-response marker.

To our knowledge, the only candidate genetic association study that included a NTC and examined the effect of genetic variation in *COMT* on the placebo response [38] used an RCT designed to test whether placebo treatment could incrementally combine three components related to placebos: diagnosis and observation (NTC arm), therapeutic apparatus (placebo acupuncture), and apparatus plus a supportive patient–practitioner relation (placebo acupuncture plus a warm-caring provider) [50]. The RCT was a 3-week trial in patients with irritable bowel syndrome (IBS), and the main outcome was reduction in IBS symptom severity. Patients in the arm that combined all the components, the strongest placebo treatment, reported the greatest symptom relief. The candidate genetic analysis performed on a subset of these patients, who gave genetic informed consent, looked at the association of rs4680 with IBS symptom severity, adequate relief, and quality of life in each of the treatment arms. Patients homozygous for the rs4680 low-activity met allele (met/met), known to have high levels of dopamine, had the greatest placebo response. The high-activity val allele homozygous (val/val)

**Table 1. Polymorphisms in candidate genes that may be part of the placebo**

Placebo pathway	Gene name	Gene symbol	Chromosomal location	Placebo SNPs	Refs
Dopamine	Catechol-O-methyltransferase	<i>COMT</i>	22q11.2	rs4680	[38]
	Monoamine oxidase	<i>MAO-A</i>	Xp11.3	rs6323, rs6609257	[43,55]
	Dopamine B hydroxylase	<i>DBH</i>	9q34	rs2873804	[43]
	Dopamine receptor 3	<i>DRD3</i>	3q13.31	rs6280	[59]
	Brain-derived neurotrophic factor	<i>BDNF</i>	11p14.1	rs6265	[66]
Serotonin	Tryptophan hydroxylase-2	<i>TPH2</i>	12q21.1	rs4570625	[75]
	5-Hydroxytryptamine transporter	<i>SLC6A4</i>	17q11.2	rs4251417	[43]
	5-Hydroxytryptamine receptor 2A	<i>HTR2A</i>	13q14.2	rs2296972, rs622337	[43]
	Serotonin transporter gene-linked polymorphic region	<i>5-HTTLPR</i>	17q11.2	Variable tandem nucleotide repeat	[75]
Opioid	Opioid receptor	<i>OPRM1</i>	6q25.2	rs510769	[69]
Endocannabinoid	Fatty acid amide hydrolase	<i>FAAH</i>	1p33	rs324420	[73]

patients had the lowest placebo response. The val/met heterozygotes had an intermediate response. Similar results were reported for another *COMT* SNP, rs4633, which is closely linked to rs4680.

A subsequent small acute-pain model placebo neuroimaging study in healthy volunteers looked at genetic variation in *COMT* in relation to brain activity in the reward system using resting-state functional magnetic resonance imaging [51]. These researchers showed that placebo response to pain in healthy volunteers supported the IBS results, such that the number of rs4680 met alleles was linearly correlated with suppression of pain in the placebo expectation laboratory paradigm. While not having a NTC, the pain stimulation in this experiment was momentary, precise, and calibrated, so we can assume that spontaneous remission and waxing and waning of illness were not potential confounders.

Interestingly, a recent laboratory study found that the rs4680 high-activity val allele was associated with a higher frequency of nocebo effects (negative placebo adverse effect) using a model of learned immunosuppression [52]. Similarly, in the IBS placebo study discussed previously, the rs4680 high-activity val allele was associated with a higher frequency of complaint reporting [40]. This association of nocebo effect with the high-activity rs4680 val allele is not necessarily unexpected, given that in the absence of any significant improvements in symptoms derived from a placebo response, val/val individuals may have more complaints or experience more adverse effects.

In addition to *COMT*, there are several other polymorphisms in the dopamine pathway that are potential placebo candidates. Monoamine oxidase A (MAO-A) has been implicated in reward pathways through its role in catalyzing the oxidation of monoamines, including dopamine. MAO-A also metabolizes serotonin and has been shown to affect serotonergic availability and signaling [53]. The *MAOA* gene is X-linked, and a common rs6323 (G to T) SNP results in a 75% reduction in enzymatic activity in females homozygous for the T allele, and males hemizygous with one T allele [54]. The association of *MAOA* with treatment response to placebo was examined in a candidate gene analysis of patients with clinical depression from four combined small placebo-controlled RCTs of three selective serotonin reuptake inhibitor antidepressants (SSRIs), venlafaxine, sertraline, or fluoxetine [55]. The primary outcome was determined by the 17-item Hamilton Depression Rating Scale (HAM-D<sub>17</sub>). Consistent with the findings described above for *COMT*, individuals with the low-activity *MAOA* genotypes and, therefore, higher basal dopamine tone, had a higher placebo response than those with the high-activity *MAOA* genotypes. The *COMT* rs4680 association with placebo response was also examined in this study, but the results were not significant. It is unclear whether the nonsignificant results with *COMT* were due to lack of power, a basic difference in the subject population, or other factors.

To our knowledge, the largest study of genetic variation in RCT patients randomized to placebo treatment examined 34 candidate genes (500 polymorphisms) in four trials of bupropion for major depressive disorder [43]. Although results for rs4680 were not reported in this trial, several

other *COMT* SNPs were associated with placebo response and placebo remission (although these associations did not survive correction for multiple comparisons). The placebo response association with *MAOA* rs6609257, a SNP associated with dopamine basal tone, was one of the associations with treatment response in the placebo arm that was significant after correction, supporting the candidacy of *MAOA* in the placebo.

Genetic variations in dopamine receptor genes that modify dopaminergic signaling also modify the function of the brain reward circuit [56,57]. Rs6280 is a common serine-to-glycine coding polymorphism in dopamine receptor 3 (*DRD3*) that results in the *DRD3* glycine form having a higher affinity for dopamine compared with the serine form [58]. A recent placebo-controlled RCT of a novel drug for treating symptoms of schizophrenia (ABT-925) examined the effects of genetic variation in *DRD3* on the Positive and Negative Syndrome Scale (PANSS) [59]. Subjects homozygous for rs6280 serine allele (S/S) had significantly better outcomes in the placebo arm than when they were treated with increasing doses of ABT-95. Consistent with other studies, this study also showed that the *COMT* rs4680 met/met subjects had a higher placebo response.

Genetic variation in dopamine beta-hydroxylase (*DBH*), an enzyme that converts dopamine to norepinephrine, similar to *COMT*, has been associated with variation in blood pressure [39] and psychiatric disease. In studies of alcohol dependence, individuals homozygous for the CC genotype of the rs1611115 *DBH* polymorphism appeared to do better on placebo and worse on naltrexone [60]. *DBH* was also one of the genes examined in the largest 34-candidate gene analysis of the placebo arm of the bupropion trial discussed above [43]. The *DBH* SNP rs2873804 survived the correction for multiple comparisons, reinforcing *DBH* as a potential candidate for a placebo response gene.

Brain-derived neurotrophic factor (BDNF) has an important role in learning and memory, mediating and maintaining turnover of dopamine [61,62]. Its functions in neuroadaptive change and response to reward stimuli [63,64] make BDNF another plausible candidate for the placebo. The rs6265 SNP in BDNF encodes a valine-to-methionine substitution at codon 66 [47]. This functional polymorphism is hypothesized to reduce activity-dependent BDNF release due to inefficient BDNF trafficking to secretory granules [65]. Genetic variation at rs6265 was associated with greater placebo-induced dopamine D2 and D3 activation in rs6265 val allele homozygotes compared with met allele carriers; however, these differences in neuronal activation did not translate into differences in placebo analgesia as assessed by the pain ratings reported [66].

These data show a consistent association of outcomes in patients and healthy volunteers treated with placebo with genes involved in dopamine metabolism and signaling, such that individuals with higher levels of dopamine or higher dopaminergic activity tended to be more likely to respond to placebo in the studies examined. Taken together, these associations provide support for dopamine pathway SNPs as placebo response genetic markers. More research in other conditions, dopamine pathway SNPs,

and with larger samples with NTCs would help to make these associations more definitive.

### Genetic variation in the opioid signaling pathway

Endogenous opioids signal through opioid receptors, and genetic variation in the mu opioid receptor gene (*OPRM1*) has been shown to modify treatment outcomes in pain studies. The analgesic effects of placebo have been shown to be mediated through activation of endogenous opioid as well dopaminergic mechanisms. In a small experimental placebo study performed on healthy volunteers, signaling in the dopamine pathway was linked to opioid receptor signaling in antinociceptive responses to placebo [26]. Rs1799971 is a functional polymorphism in the *OPRM1* gene that results in an asparagine-to-aspartic acid change at codon 40. The aspartic acid variant of the receptor was found to reduce receptor function across several studies [67,68]. The association of rs1799971 with placebo response in healthy volunteers was studied in an experimental model of placebo-induced analgesia [69]. In this study, placebo-induced activation of dopamine neurotransmission in the nucleus accumbens was greater in asparagine homozygotes compared with aspartic acid-allele carriers, suggesting that genetic variation in *OPRM1* also contributes to variability in the placebo response.

Whether the association of *OPRM1* with placebo-induced analgesia is generalizable to other nonpain paradigms of placebo response remains to be determined. Indeed, work on genetic variation in *OPRM1* has examined associations with the reward-based addictive effects of psychostimulants (e.g., amphetamine) and opioid drugs (e.g., morphine). Several of these studies have shown differential outcomes in the placebo and drug treatment arms as a function of genetic variation in *OPRM1* [60,70]; but, again, it is impossible to determine whether the effect modification of treatment outcomes in the placebo arm was a function of placebo response or of genetic variation effects at baseline in the absence of a NTC.

### Genetic variation in endocannabinoids and serotonin signaling pathways

The two other neurological pathways implicated in the placebo response involve endocannabinoid and serotonergic signaling. Endocannabinoids are neurotransmitters that signal through the cannabinoid receptors, CB1 and CB2, and have been implicated in analgesia [71]. Placebo laboratory studies have further implicated endocannabinoids in placebo analgesia, providing a rationale for considering genetic variation in the endocannabinoid pathway in the placebo response [72]. The effects of genetic variation in fatty acid amide hydrolase (*FAAH*), the major degradative enzyme of endocannabinoids, was examined in a small study [73] that used some of the same subjects as the *OPRM1* placebo experiment described above [69]. This study found that homozygotes for the *FAAH* Pro129 allele (known to increase chronically endocannabinoid levels in the brain in response to pain) reported more placebo-induced analgesia, supporting the endocannabinoid pathway genes as loci worth exploring further for candidacy in the placebo response.

Serotonin is a neurotransmitter that is important in regulating mood, appetite, and sleep. Given the high rates

of placebo responses in RCTs of treatments for mood disorders [31], the serotonin pathway is important to examine for possible placebo response-related genes. SSRIs are antidepressants thought to block the uptake of serotonin. There is some evidence from candidate gene studies that serotonin pathway genes are associated with placebo responses of depression and anxiety. The previously mentioned study that examined 34 candidate genes for placebo response in depression included several genes in the serotonergic pathway and reported significant association between placebo remission with 5-hydroxytryptamine (serotonin) transporter *SLC6A4* rs4251417, *HTR2A* rs2296972, and rs622337 [43]. Unfortunately one of the largest GWAS conducted to determine the effectiveness of different treatments for people with major depression, the Sequenced Treatment Alternatives to Relieve Depression (STAR\*D) Study did not include a placebo control [74].

Serotonin-mediated placebo response genes have also been examined in a small RCT of social anxiety disorder (SAD). In this small candidate gene PET study of SAD, reduction in anxiety symptoms in response to placebo was accompanied by a reduction in stress-related amygdala activity [75]. This reduction was limited to subjects homozygous at two serotonin pathway-related polymorphisms, rs4570625 in the tryptophan hydroxylase-2 (*TPH2*) gene promoter and the long allele of the serotonin transporter-linked polymorphic region (*5-HTTLPR*). Although this study was limited by its small size and by not having an NCT, these findings, in the absence of other evidence, suggest that genetic variation in serotonin pathway polymorphisms *TPH2* and *5-HTTLPR* are potential biomarkers of placebo response in SAD.

Given the complex interplay of behavior, expectation, neurotransmitter signaling, disease, and the context of the medical treatment ritual, the molecular pathways and genes involved in contributing to placebo responses is unfolding as a potentially complex network.

### The placebo: main and interaction effects in RCT design

Although we do not yet have a comprehensive understanding of the placebo, it is prudent to consider issues that might arise and the potential impact on RCT design. In general, the placebo arm is considered to be an adequate control for outcomes in the active treatment arm of RCTs. However, if the placebo response does, indeed, vary by genotype, we might expect challenges with confounding, potential gene–drug–placebo effect modification and disease-specific effects.

The efficacy of a drug is determined by the difference between the aggregate outcomes of individuals randomized to drug versus placebo treatment. Therefore, the accuracy of the estimate of drug efficacy, especially in smaller trials depends on the randomization balancing the numbers of placebo responders by genotype across treatment arms. If by chance, in trials where the placebo response is known to be high (such as IBS [76]), there are more genetically predisposed placebo responders in the placebo arm than in the drug arm, the estimate of drug efficacy will be confounded by genotype and the results biased towards the null. If this imbalance is not accounted

for, it would be expected to be more of a problem in smaller trials than larger trials. Ideally, RCTs would be designed such that the randomization balanced genetically predisposed placebo responders across all arms of a trial.

To date, pharmacogenomic research has concentrated on gene–drug interactions in the context of the drug treatment. However, because many of the putative placebo genes or pathways are also drug targets, there is the possibility that these drugs could interact with the placebo response and, thus, compromise the assumption that drug and placebo responses are additive. Furthermore, the effect of genetic variation on placebo and/or drug response, a combined gene–drug–placebo interaction, could result in differential outcomes in the placebo and drug treatment arms as a function of genotype. Although three-way interactions are considered unlikely, there are several reports in the *COMT* literature that provide reasonable supporting evidence [34,35,39,41,44,59]. For example, in a small RCT of tolcapone (a *COMT* inhibitor used to treat Parkinson's disease), individuals homozygous for the low-activity *COMT* rs4680 met allele performed better when treated with placebo than when treated with drug [34]. Conversely, high-activity val allele homozygotes improved with tolcapone treatment compared with placebo. These findings were interpreted as the drug 'not working' for met allele homozygotes, but a gene–placebo–drug interaction hypothesis could also be applied to these differential outcomes. Although most of these studies are small and focused on mental performance outcomes, a *COMT*–drug–placebo effect modification was also observed in the Women's Genome Health Study, a large placebo controlled RCT of aspirin and vitamin E for the primary prevention of cardiovascular disease [39]. In this study, not only did clinical outcomes in both the placebo and drug treatment arms vary as a function of *COMT* genotype, but an association with baseline cardiovascular disease was also reported. Of course, without a NTC, interpretation of results from the placebo arm should be approached with an abundance of caution.

The diversity of diseases associated with *COMT* is striking, and ranges from dopamine-associated disorders such as Parkinson's disease [77] and schizophrenia [78], to epinephrine- and norepinephrine-related disorders, such as hypertension [79], pre-eclampsia [80], and major cardiovascular disease [39]. *COMT* enzymatic activity has been shown to be inhibited by several drugs, including tolcapone [35], quercetin [81], and vitamin E [82]. This potential intersection of disease, drug, and placebo effects suggests that *COMT* is an excellent model for the sophisticated network analyses that may be necessary to fully appreciate the potential complexity of the placebo. Large-scale integration of genomic effects from proteomic, metabolomic, and small molecule-induced genome-wide transcriptional studies have greatly increased our power to identify and examine complex perturbations in these molecular networks that can compromise or enhance drug efficacy and safety [83,84]. Despite the importance of placebo controls in drug development, these systems biology and pharmacology studies do not provide any data on the placebo condition. This is partly because these studies are derived in cellular model systems and partly because the

concept of interaction effects between drug and placebo treatment is novel and remains to be proven. As large-scale placebo response -omics data become available, it may then be possible to identify disease and or drug specific placebo modules by mapping these molecules and their relations to systems biology frameworks, such as the interactome [85,86].

The potential complexity of this network is rapidly escalated when one considers that different diseases and different placebo pathways may produce different responses in different patients. Consider, for instance, an individual who is dopaminergic dominant and tends to be more responsive to placebo in pain studies: their placebo response in a depression trial might differ significantly depending on whether they were serotonergic dominant or recessive. This may help explain why it has been so difficult to identify consistent and reliable placebo responders [11]. Therefore, understanding the net effect of the placebo and how this varies in the context of specific diseases and treatments may be an important consideration in personalized medicine.

While studies have not as yet been conducted to identify genes and drugs that modify placebo response, hypothetically there may even be situations in which one might opt to intentionally use a drug to modify the placebo response. For instance, purposefully using a drug to inhibit the placebo response in clinical trials could minimize the placebo response and allow for a more accurate measurement of the drug effect. In this case, the placebo-modifying drug would be administered to both the drug treatment and placebo arm of the trial, and any potential drug–drug or gene–drug interactions would have to be well characterized.

Given that so many future RCTs already include a placebo treatment arm and plan to collect -omics data, we propose that a cost-effective approach to elucidating the placebo would be to simply add NTCs to these studies. Of course, if this type of data already exists, conducting analyses designed to identify placebo response markers would also be worthwhile. Such an approach would not be limited to disease or treatment type and would constitute a concerted and expeditious effort to populate the placebo, perhaps to great clinical and pharmaceutical drug development benefit.

### Clinical considerations

Information on whether a patient is likely to be a placebo responder or nonresponder is not a disease or condition that would warrant automatic consideration in routine clinical care. The placebo seems less critical than knowing whether a singular genetic variant of a cancer will respond to particular tailored pharmaceutical interventions, yet, there may be important clinical implications in routine care. For example, good evidence suggests that persons homozygous for the low-activity met allele at *COMT* rs4680 (met/met) are more likely to respond to morphine than those homozygous for the val allele (val/val) [87,88]. An individual difference in morphine metabolism is the usual interpretation; however, this research is based on cohort studies of patients without placebo controls. If replication of these studies with proper

placebo controls demonstrate that, in fact, this difference is due to differential placebo responses or even placebo–drug interactions, a *COMT* profile could be helpful in determining an initial dose for morphine treatment (and possibly other pain medications). This question of personalizing drug doses based on genetic placebo profiles is likely to be significant in conditions other than pain that are known to have high variability in both drug and placebo responses, such as functional urinary and bowel conditions, and symptoms of fatigue, nausea, hot flashes, depression, and anxiety. Furthermore, the usefulness of a recently proposed strategy of open-label honest placebo treatments in such conditions as IBS [89], acute episodic migraine attack [90], and depression [91] could prove more feasible with knowledge of a patient's placebome.

### Ethical considerations

If our interpretation of this early research on the placebome and the interaction of disease, drug, and genes has validity and stands the test of further inquiry, ethical issues will have to be examined. If a genetic profile(s) of placebo responders can be established, what are the ethical implications? Can, and should, physicians test for genetic placebo response propensities? Can patients refuse permission to be tested? Should patients be told about their propensity? Can patients refuse to know or to have this designation in their medical records? Can and how should physicians ethically utilize this information if it appears incidentally in genetic testing? Resolution of these issues will depend on how the entire question of genetic information will eventually be incorporated in routine clinical care. Nonetheless, from our perspective, the ethical principles of autonomy, transparency, and respect for person should remain paramount even as genetic information becomes more easily accessible [92–95]. Furthermore, such ethical issues would have to be considered in the context of shared decision-making and patient's personal values and preferences [96]. Other issues might include whether it is feasible and ethical to modify the quality of the clinical encounter of patient's treatment because they are likely placebo responders or nonresponders. And, finally, how does knowing one is a placebo responder affect one's placebo response?

Whether and how information of a placebome should be applied to RCTs could also have complex ethical implications. A key goal of the RCT is to detect a drug–placebo difference. There is a long and unsuccessful history of attempts to increase the efficiency of RCTs with placebo run-in periods that eliminate placebo responders [97–99]. Could placebome data lead to new 'enrichment' strategies that could eliminate *a priori* high placebo responders in RCTs? Our discussion of placebo–drug interactions suggests that genetic profiles have the possibility of becoming an alternative strategy to make detection of drug–placebo difference more efficient. Several questions arise from implementing such an innovation in the regulatory space. Would there be a benefit to using these enrichment strategies in trial design? How would the US FDA label be affected? Obviously, regulatory agencies would need to determine the medicolegal implications of such an enrichment strategy.

### Limitations

The ability to predict the placebo response assumes that it is a stable trait that is not influenced by the many individual states, for example personal and cultural beliefs, conscious and nonconscious expectations, previous experiences with healthcare, severity of illness, history of illness, and research design factors, such as treatment duration, number of active arms in the trial, practitioner characteristics and their interaction factors, such as the quality of the entire therapeutic encounter. Therefore, these individual, contextual or situational variables present an important limitation on any simplistic or reductionist genetic model developed to predict placebo response [10,100]. Although it seems plausible that genetic factors are predictive of a relative disposition to interact with such state and environmental influences, there may be epigenetic effects that are also critical to placebo responses. Furthermore, given the potential for different placebo pathways, in different classes of disease and disorder, consideration needs to be given to developing disease- or treatment-specific placebo panels from the placebome. The number of genes required to build an effective placebo response screening panel remains to be determined. With small candidate gene studies lacking NTCs, there are significant limitations to available data on the placebome. Future studies will have to be large to account for the many environmental, genetic, and drug interactions. Given that, in the absence of definitive studies, the potential of drug treatments to interact with placebo response genes remains hypothetical, the size of these interaction effects relative to placebo effects is not known, and it remains to be seen how large a trial would have to be to measure this effect modification. In the case where interactions are significant, refinement of RCT design might be a real possibility.

### Concluding remarks

The placebo response is a complex phenotype with an unfolding physiology. Based on the evidence summarized here, we can speculate that the placebome comprises multiple intersecting pathways that have upstream or downstream effects on dopamine and opioid function, depending on the disease or disorder being treated.

#### Box 1. Outstanding questions

- What proportion of the variability in placebo response can be attributed to the placebome?
- How do shifts in environment and culture interact with the placebome?
- To what extent are there disease specific submodules in the placebome?
- Do gene–drug–placebo interaction effects exist? How do these affect outcomes in clinical trials?
- What design and analysis issues arise from using placebo response biomarkers in RCTs?
- What are the regulatory and ethical implications of using placebo response biomarkers in clinical trials?
- How might treatment in the clinic be modified if a patient is genetically predisposed to respond to placebo? In what kinds of condition would drug dosages be modified if a patient has a disposition to have a higher placebo response?
- Will knowing if you are genetically predisposed to be a placebo responder change your placebo response?

The endocannabinoid and serotonin pathways may also be involved, but the evidence is more limited. The potential overlap between placebo, drug treatment, and disease add to the complexity of the placebo and underscore the importance of understanding how it fits into larger more complex biological networks. An important next step in describing the placebo would be to include a NTC in placebo-controlled RCTs that plan to capture -omics data. This approach might be cost-effective and allow for a broad view of placebo response genes and other molecules across varying conditions and treatments. Knowledge of the placebo has the potential to guide development of novel strategies for identifying placebo responders and clinical trial design. However, numerous attendant regulatory, ethical, and clinical questions would need to be addressed before such innovations could be integrated into drug development and clinical care (Box 1). Given the potential benefits in terms of research design, reduction in the cost of clinical trials, and safer, more effective, personalized medicines, continued placebo research is justified.

#### Acknowledgments

We thank Daniel Chasman, Irving Kirsch and Frank Miller for helpful discussions. We acknowledge the following funding sources: NIH/NCCAM T32AT000051 to K.T.H. NIH/NCCAM grants # 2K24 AT004095, # R01 AT005280, R01 AT004662 and P01 AT006663 to T.J.K.

#### References

- Raicek, J.E. *et al.* (2012) Placebos in 19th century medicine: a quantitative analysis of the BMJ. *BMJ* 345, e8326
- Kaptchuk, T.J. (1998) Intentional ignorance: a history of blind assessment and placebo controls in medicine. *Bull. Hist. Med.* 72, 389–433
- Kaptchuk, T.J. (1998) Powerful placebo: the dark side of the randomised controlled trial. *Lancet* 351, 1722–1725
- Atlas, L.Y. and Wager, T.D. (2014) A meta-analysis of brain mechanisms of placebo analgesia: consistent findings and unanswered questions. *Handb. Exp. Pharmacol.* 225, 37–69
- Benedetti, F. (2013) Placebo and the new physiology of the doctor-patient relationship. *Physiol. Rev.* 93, 1207–1246
- Benedetti, F. (2009) *Placebo Effects: Understanding The Mechanisms In Health And Disease*, Oxford University Press
- Finniss, D.G. and Benedetti, F. (2005) Mechanisms of the placebo response and their impact on clinical trials and clinical practice. *Pain* 114, 3–6
- Wechsler, M.E. *et al.* (2011) Active albuterol or placebo, sham acupuncture, or no intervention in asthma. *N. Engl. J. Med.* 365, 119–126
- Servick, K. (2014) Outsmarting the placebo effect. *Science* 345, 1446–1447
- Horing, B. *et al.* (2014) Prediction of placebo responses: a systematic review of the literature. *Front. Psychol.* 5, 1079
- Kaptchuk, T.J. *et al.* (2008) Do 'placebo responders' exist? *Contemp. Clin. Trials* 29, 587–595
- Finniss, D.G. *et al.* (2010) Biological, clinical, and ethical advances of placebo effects. *Lancet* 375, 686–695
- Levine, J.D. *et al.* (1978) The narcotic antagonist naloxone enhances clinical pain. *Nature* 272, 826–827
- Levine, J.D. and Gordon, N.C. (1984) Influence of the method of drug administration on analgesic response. *Nature* 312, 755–756
- Levine, J.D. *et al.* (1981) Analgesic responses to morphine and placebo in individuals with postoperative pain. *Pain* 10, 379–389
- Bingel, U. *et al.* (2006) Mechanisms of placebo analgesia: rACC recruitment of a subcortical antinociceptive network. *Pain* 120, 8–15
- Zubieta, J.K. *et al.* (2005) Placebo effects mediated by endogenous opioid activity on mu-opioid receptors. *J. Neurosci.* 25, 7754–7762
- Zubieta, J.K. and Stohler, C.S. (2009) Neurobiological mechanisms of placebo responses. *Ann. N. Y. Acad. Sci.* 1156, 198–210
- Benedetti, F. and Amanzio, M. (2013) Mechanisms of the placebo response. *Pulm. Pharmacol. Ther.* 26, 520–523
- Amanzio, M. and Benedetti, F. (1999) Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. *J. Neurosci.* 19, 484–494
- Benedetti, F. *et al.* (1997) Blockade of placebo hyperalgesia by the cholecystokinin antagonist proglumide. *Pain* 71, 135–140
- Benedetti, F. (1996) The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia. *Pain* 64, 535–543
- Benedetti, F. *et al.* (1995) Potentiation of placebo analgesia by proglumide. *Lancet* 346, 1231
- Benedetti, F. *et al.* (2011) Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors. *Nat. Med.* 17, 1228–1230
- Price, D.D. *et al.* (1999) An analysis of factors that contribute to the magnitude of placebo analgesia in an experimental paradigm. *Pain* 83, 147–156
- Scott, D.J. *et al.* (2008) Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. *Arch. Gen. Psychiatry* 65, 220–231
- de la Fuente-Fernandez, R. *et al.* (2001) Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. *Science* 293, 1164–1166
- Lidstone, S.C. *et al.* (2010) Effects of expectation on placebo-induced dopamine release in Parkinson disease. *Arch. Gen. Psychiatry* 67, 857–865
- Leuchter, A.F. *et al.* (2002) Changes in brain function of depressed subjects during treatment with placebo. *Am. J. Psychiatry* 159, 122–129
- Mayberg, H.S. *et al.* (2002) The functional neuroanatomy of the placebo effect. *Am. J. Psychiatry* 159, 728–737
- Kirsch, I. *et al.* (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. *PLoS Med.* 5, e45
- Turner, E.H. *et al.* (2008) Selective publication of antidepressant trials and its influence on apparent efficacy. *N. Engl. J. Med.* 358, 252–260
- Lachman, H.M. *et al.* (1996) Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. *Pharmacogenetics* 6, 243–250
- Bitsios, P. and Roussos, P. (2011) Tolcapone, COMT polymorphisms and pharmacogenomic treatment of schizophrenia. *Pharmacogenomics* 12, 559–566
- Farrell, S.M. *et al.* (2012) COMT Val(158)Met genotype determines the direction of cognitive effects produced by catechol-O-methyltransferase inhibition. *Biol. Psychiatry* 71, 538–544
- Giakoumakis, S.G. *et al.* (2008) Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT Val158Met polymorphism. *Neuropsychopharmacology* 33, 3058–3068
- Hall, K.T. and Kaptchuk, T.J. (2013) Genetic biomarkers of placebo response: what could it mean for future trial design? *Clin. Invest.* 3, 311–314
- Hall, K.T. *et al.* (2012) Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome. *PLoS ONE* 7, e48135
- Hall, K.T. *et al.* (2014) Polymorphisms in catechol-O-methyltransferase modify treatment effects of aspirin on risk of cardiovascular disease. *Arterioscler. Thromb. Vasc. Biol.* 34, 2160–2167
- Hall, K.T. *et al.* (2015) Conscientiousness is modified by genetic variation in catechol-O-methyltransferase to reduce symptom complaints in IBS patients. *Brain Behav.* 5, e00294
- Hamidovic, A. *et al.* (2010) Catechol-O-methyltransferase val158met genotype modulates sustained attention in both the drug-free state and in response to amphetamine. *Psychiatr. Genet.* 20, 85–92
- Tchivileva, I.E. *et al.* (2010) Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study. *Pharmacogenet. Genomics* 20, 239–248



- 43 Tiwari, A.K. *et al.* (2013) Analysis of 34 candidate genes in bupropion and placebo remission. *Int. J. Neuropsychopharmacol.* 16, 771–781
- 44 Weickert, T.W. *et al.* (2004) Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. *Biol. Psychiatry* 56, 677–682
- 45 Meyer-Lindenberg, A. *et al.* (2005) Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. *Nat. Neurosci.* 8, 594–596
- 46 Yavich, L. *et al.* (2007) Site-specific role of catechol-O-methyltransferase in dopamine overflow within prefrontal cortex and dorsal striatum. *J. Neurosci.* 27, 10196–10209
- 47 Sherry, S.T. *et al.* (2001) dbSNP: the NCBI database of genetic variation. *Nucleic Acids Res.* 29, 308–311
- 48 McLeod, H.L. *et al.* (1994) Ethnic differences in erythrocyte catechol-O-methyltransferase activity in black and white Americans. *J. Pharmacol. Exp. Ther.* 270, 26–29
- 49 Palmatier, M.A. *et al.* (1999) Global variation in the frequencies of functionally different catechol-O-methyltransferase alleles. *Biol. Psychiatry* 46, 557–567
- 50 Kaptchuk, T.J. *et al.* (2008) Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. *BMJ* 336, 999–1003
- 51 Yu, R. *et al.* (2014) Placebo analgesia and reward processing: integrating genetics, personality, and intrinsic brain activity. *Hum. Brain Mapp.* 35, 4583–4593
- 52 Wendt, L. *et al.* (2014) Catechol-O-methyltransferase Val158Met polymorphism is associated with somatosensory amplification and nocebo responses. *PLoS ONE* 9, e107665
- 53 Mickey, B.J. *et al.* (2008) Monoamine oxidase A genotype predicts human serotonin 1A receptor availability in vivo. *J. Neurosci.* 28, 11354–11359
- 54 Hotamisligil, G.S. and Breakefield, X.O. (1991) Human monoamine oxidase A gene determines levels of enzyme activity. *Am. J. Hum. Genet.* 49, 383–392
- 55 Leuchter, A.F. *et al.* (2009) Monoamine oxidase a and catechol-O-methyltransferase functional polymorphisms and the placebo response in major depressive disorder. *J. Clin. Psychopharmacol.* 29, 372–377
- 56 Diaz, J. *et al.* (2000) Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. *J. Neurosci.* 20, 8677–8684
- 57 Bouthenet, M.L. *et al.* (1991) Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. *Brain Res.* 564, 203–219
- 58 Lundstrom, K. *et al.* (1998) Mapping of dopamine D3 receptor binding site by pharmacological characterization of mutants expressed in CHO cells with the Semliki Forest virus system. *J. Recept. Signal Transduct. Res.* 18, 133–150
- 59 Bhatena, A. *et al.* (2013) Association of dopamine-related genetic loci to dopamine D3 receptor antagonist ABT-925 clinical response. *Transl. Psychiatry* 3, e245
- 60 Arias, A.J. *et al.* (2014) Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans. *Am. J. Addict.* 23, 288–293
- 61 Altar, C.A. *et al.* (1992) Brain-derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo. *Proc. Natl. Acad. Sci. U.S.A.* 89, 11347–11351
- 62 Goggi, J. *et al.* (2002) Modulation of neurotransmitter release induced by brain-derived neurotrophic factor in rat brain striatal slices in vitro. *Brain Res.* 941, 34–42
- 63 Miczek, K.A. *et al.* (2011) Escalated or suppressed cocaine reward, tegmental BDNF, and accumbal dopamine caused by episodic versus continuous social stress in rats. *J. Neurosci.* 31, 9848–9857
- 64 Krishnan, V. *et al.* (2007) Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. *Cell* 131, 391–404
- 65 Vaccarino, V. *et al.* (2008) Association of major depressive disorder with serum myeloperoxidase and other markers of inflammation: a twin study. *Biol. Psychiatry* 64, 476–483
- 66 Pecina, M. *et al.* (2014) Valence-specific effects of BDNF Val66Met polymorphism on dopaminergic stress and reward processing in humans. *J. Neurosci.* 34, 5874–5881
- 67 Zhang, Y. *et al.* (2005) Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. *J. Biol. Chem.* 280, 32618–32624
- 68 Krosiak, T. *et al.* (2007) The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. *J. Neurochem.* 103, 77–87
- 69 Pecina, M. *et al.* (2015) Effects of the mu opioid receptor polymorphism (OPRM1 A118G) on pain regulation, placebo effects and associated personality trait measures. *Neuropsychopharmacology* 40, 957–965
- 70 Chen, A.C. *et al.* (2013) Variation in mu-opioid receptor gene as a moderator of naltrexone treatment to reduce heavy drinking in a high functioning cohort. *J. Alcohol. Drug Depend.* 1, 101
- 71 Hohmann, A.G. (2002) Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. *Chem. Phys. Lipids* 121, 173–190
- 72 Colloca, L. *et al.* (2008) The role of learning in nocebo and placebo effects. *Pain* 136, 211–218
- 73 Pecina, M. *et al.* (2014) FAAH selectively influences placebo effects. *Mol. Psychiatry* 19, 385–391
- 74 Hunter, A.M. *et al.* (2013) A genome-wide association study of a sustained pattern of antidepressant response. *J. Psychiatr. Res.* 47, 1157–1165
- 75 Furmark, T. *et al.* (2008) A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety. *J. Neurosci.* 28, 13066–13074
- 76 Patel, S.M. *et al.* (2005) The placebo effect in irritable bowel syndrome trials: a meta-analysis. *Neurogastroenterol. Motil.* 17, 332–340
- 77 Bialecka, M. *et al.* (2008) The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications. *Pharmacogenet. Genomics* 18, 815–821
- 78 Gatt, J.M. *et al.* (2015) Specific and common genes implicated across major mental disorders: a review of meta-analysis studies. *J. Psychiatr. Res.* 60C, 1–13
- 79 Annerbrink, K. *et al.* (2008) Catechol O-methyltransferase val158-met polymorphism is associated with abdominal obesity and blood pressure in men. *Metabolism* 57, 708–711
- 80 Kanasaki, K. *et al.* (2008) Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. *Nature* 453, 1117–1121
- 81 Wright, B. *et al.* (2010) Platelet-mediated metabolism of the common dietary flavonoid, quercetin. *PLoS ONE* 5, e9673
- 82 Thithapandha, A. and Srinoot, P. (1972) Comparative inhibitory effects of vitamins on methylating enzymes. *Comp. Gen. Pharmacol.* 3, 139–144
- 83 Silverman, E.K. and Loscalzo, J. (2013) Developing new drug treatments in the era of network medicine. *Clin. Pharmacol. Ther.* 93, 26–28
- 84 Antman, E.S. *et al.* (2012) Systems pharmacology, pharmacogenetics, and clinical trial design in network medicine. *Wiley Interdiscip. Rev. Syst. Biol. Med.* 4, 367–383
- 85 Menche, J. *et al.* (2015) Uncovering disease-disease relationships through the incomplete interactome. *Science* 347, 1257601
- 86 Vidal, M. *et al.* (2011) Interactome networks and human disease. *Cell* 144, 986–998
- 87 Rakvag, T.T. *et al.* (2008) Genetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer patients with pain. *Mol. Pain* 4, 64
- 88 Rakvag, T.T. *et al.* (2005) The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. *Pain* 116, 73–78
- 89 Kaptchuk, T.J. *et al.* (2010) Placebos without deception: a randomized controlled trial in irritable bowel syndrome. *PLoS ONE* 5, e15591
- 90 Kam-Hansen, S. *et al.* (2014) Altered placebo and drug labeling changes the outcome of episodic migraine attacks. *Sci. Transl. Med.* 6, 218ra5
- 91 Kelley, J.M. *et al.* (2012) Open-label placebo for major depressive disorder: a pilot randomized controlled trial. *Psychother. Psychosom.* 81, 312–314
- 92 Hazin, R. *et al.* (2013) Ethical, legal, and social implications of incorporating genomic information into electronic health records. *Genet. Med.* 15, 810–816

- 93 Josko, D. (2014) Personalized medicine and ethics. *Clin. Lab. Sci.* 27, 185–190
- 94 Korf, B.R. and Rehm, H.L. (2013) New approaches to molecular diagnosis. *JAMA* 309, 1511–1521
- 95 Ormond, K.E. and Cho, M.K. (2014) Translating personalized medicine using new genetic technologies in clinical practice: the ethical issues. *Per. Med.* 11, 211–222
- 96 Burke, W. *et al.* (2014) Essential elements of personalized medicine. *Urol. Oncol.* 32, 193–197
- 97 Katz, N. (2005) Methodological issues in clinical trials of opioids for chronic pain. *Neurology* 65 (Suppl. 4), S32–S49
- 98 Lee, S. *et al.* (2004) Does elimination of placebo responders in a placebo run-in increase the treatment effect in randomized clinical trials? A meta-analytic evaluation. *Depress. Anxiety* 19, 10–19
- 99 Straube, S. *et al.* (2008) Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. *Br. J. Clin. Pharmacol.* 66, 266–275
- 100 Caspi, O. and Bootzin, R.R. (2002) Evaluating how placebos produce change. Logical and causal traps and understanding cognitive explanatory mechanisms. *Eval. Health Prof.* 25, 436–464